Neos Functional Medicine

Neos Functional Medicine At Neos FM, we go beyond symptom management—we uncover and tackle the root causes of your health concerns. https://linktr.ee/neosfm

09/02/2026

Here’s what the video doesn’t tell you: it was my gut, my thyroid, and my training.

A decade of stress and life events wrecked my gut. Ten years on oral contraceptives didn’t help. All of it was quietly dragging my thyroid down. And I was overtraining on top of it, which I would not have believed if you told me at the time. My nutrition was dialed in the entire way.

Every provider I saw stopped at “your TSH is in range… colonoscopy and endoscopy is normal.” Nobody looked beyond that….

So I reset my foundations, fixed my gut, changed how I trained, and managed my own care. Then I tested my genetics, and that was the part that reframed everything. Struggles I had written off as bad luck or bad discipline finally had an explanation, and I stopped guessing about what my body needs to stay ahead of.

I turn 35 this month and I have never been healthier. And I never had to uproot my life to get here.

That is the exact work I do for men and women now. Finding the why instead of stopping at the range.

DM LABS for a functional lab review or discussion about genetic testing that provides real answers. FL and CA residents only.

Not medical advice. Education only.

Lilly moves to make retatrutide a biologic. Here is why the pathway can matter as much as the molecule.Retatrutide is in...
07/27/2026

Lilly moves to make retatrutide a biologic. Here is why the pathway can matter as much as the molecule.

Retatrutide is investigational and not FDA approved. On July 23, 2026 Eli Lilly said it plans to file a Biologics License Application (BLA), currently expected in Q1 2027.

So why care about a filing pathway? Because the route a therapy takes shapes who can access it, and how. If retatrutide is ultimately licensed as a biologic, the traditional 503A and 503B compounding exemptions generally would not apply.

What we know: Lilly announced plans to pursue approval through a BLA. Retatrutide remains investigational. If licensed as a biologic, standard compounding exemptions generally would not apply.

What we do not know yet: whether or when the FDA approves it, final labeling, availability, pricing, or timing, and whether this route reshapes how other complex peptides get classified.

This is not an approval announcement. It is a regulatory development worth understanding as peptide therapeutics get more sophisticated.

If you are new here, hi. I am PA Pappas. I break down the science and the policy behind peptide and metabolic medicine so you can tell real signal from hype. Follow Chloe Pappas, PA-C | Men’s Health and PA Pappas || Neos Functional Medicine for the regulatory updates that actually affect access.

not medical advice, education only

Sources: Eli Lilly public statements on retatrutide regulatory plans (July 2026); FDA framework on biologics licensure and 503A and 503B compounding.

SEO keywords: retatrutide biologic status, retatrutide FDA approval timeline, Biologics License Application peptides, 503A 503B compounding biologics, GLP1 GIP glucagon triple agonist

Day 2 of the FDA peptide meeting is done. Here is where all three of today’s votes landed.DSIP: recommended AGAINST, 7 t...
07/24/2026

Day 2 of the FDA peptide meeting is done. Here is where all three of today’s votes landed.

DSIP: recommended AGAINST, 7 to 6 with 1 abstention. The first peptide the panel voted down this week.
Epitalon: recommended FOR, 7 to 4.
Semax: recommended FOR, 8 to 5 with 1 abstention.

One important thing to understand: this was the Pharmacy Compounding Advisory Committee (PCAC), which is an advisory panel only. Their job is to make recommendations. These votes are NOT bans and they are NOT approvals. Nothing changes today. The FDA takes these recommendations into account and makes the final call on the 503A compounding bulks list at a later date, and it does not have to follow the panel.

So what it means moving forward: across the two day meeting, 6 peptides were recommended for compounding and 1 (DSIP) was recommended against. Now we wait on the FDA’s final decision, which is the ruling that actually determines what compounding pharmacies can legally make.

Follow PA Pappas || Neos Functional Medicine and Chloe Pappas, PA-C | Men’s Health for what the FDA decides next.

Source: FDA Pharmacy Compounding Advisory Committee, July 2026 meeting (Docket FDA-2025-N-6895).

Not medical advice, education only.

The FDA advisory panel voted today, and 4 peptides cleared.Today the Pharmacy Compounding Advisory Committee voted in fa...
07/24/2026

The FDA advisory panel voted today, and 4 peptides cleared.

Today the Pharmacy Compounding Advisory Committee voted in favor of BPC 157, KPV, TB 500 and MOTS c for the compounding list. Both BPC 157 and KPV passed 8 to 6 with 1 abstention. TB 500 and MOTS c also passed, with exact tallies not yet broken out in coverage. The panel voted this way against the recommendation of FDA staff scientists.

3 more peptides get voted on tomorrow. Follow Chloe Pappas, PA-C | Men’s Health for tomorrow night results.

Sources: STAT News, NPR, The Hill, KPBS, and the FDA Pharmacy Compounding Advisory Committee meeting on July 23 2026.

Not medical advice, education only.

7 peptides. One FDA vote. Happening today and tomorrow.This week the FDA Pharmacy Compounding Advisory Committee is deci...
07/23/2026

7 peptides. One FDA vote. Happening today and tomorrow.

This week the FDA Pharmacy Compounding Advisory Committee is deciding whether seven popular peptides can stay legal to compound. Swipe for the biology on each one.

Today, July 23: BPC-157, KPV, TB-500 and MOTS-c
Tomorrow, July 24: Emideltide (DSIP), Epitalon and Semax

FDA staff scientists have recommended against adding all seven, citing limited safety and efficacy evidence. These are advisory votes, not final rules.

Come back tonight and tomorrow night for the results as each day of the meeting wraps.

Sources: FDA Pharmacy Compounding Advisory Committee briefing documents (July 2026), NBC News, The Washington Post, Drug Topics.

Not medical advice, education only. Follow Chloe Pappas, PA-C | Men’s Health and for the updates. neosfm.com

🚨 Save this before your next doctor's appointment.Most people get a basic panel, hear "everything looks normal," and wal...
07/05/2026

🚨 Save this before your next doctor's appointment.

Most people get a basic panel, hear "everything looks normal," and walk out with almost no real information. But a standard CBC tells you nothing about your thyroid, your hormones, your true heart risk, or where your iron and key nutrients actually sit.

This is the complete lab order I wish everyone knew to ask for: full blood count, a complete thyroid panel, fasting metabolic markers, full cholesterol including ApoB and Lp(a), hormones run the right way, and the nutrients most people are quietly low in.
Male over 40? Add PSA.

And MOST importantly, get you a medical provider that listens to how you are feeling, and finds an answer FOR you.

Your doctor works FOR you. You are allowed to ask for more. You deserve the full picture of your health, not a guess.

📌 SAVE this so you have the full checklist ready at your next visit.

📤 SHARE it with someone who keeps putting their health on the back burner.

➕ FOLLOW and for more on labs, hormones, and living longer and stronger.

*not medical advice, education only
*always talk to your own provider about which labs are right for you
*the right panel varies by person, age, symptoms, and history
*please do not try to interpret your own labs
*this is not a diagnosis or a treatment plan . .

What the FDA peptide news actually means. 👇👇Quick clarity first. FDA approved means a drug went through clinical trials ...
07/04/2026

What the FDA peptide news actually means. 👇👇

Quick clarity first.
FDA approved means a drug went through clinical trials and the FDA vetted its safety and effectiveness for a specific use. Very few peptides have ever cleared that bar.

This July review is a different thing. The FDA is weighing seven peptides for the 503A Bulks List, which decides what licensed compounding pharmacies can prepare for a patient with a prescription. So it is about compounding access, not an approval stamp, and not a ban.

Where it stands:
FDA staff recommended against adding these seven, but that is a staff opinion, not the final ruling. The committee votes this week and only guides the FDA. In 2022, staff advised against compounded glutathione and the committee voted 8 to 5 to add it anyway. Nothing is settled.

If you take peptides or have been curious about them, this could shape what your provider can legally compound. Worth understanding before the headlines decide it for you.

Know someone who takes peptides? Send this their way. And follow PA Pappas || Neos Functional Medicine and Chloe Pappas, PA-C | Men’s Health for real, evidence based, clinician guided updates as this develops.

Sources: FDA Advisory Committee calendar and July 2026 PCAC briefing documents; 2022 PCAC glutathione vote records.

Educational content. Not medical or legal advice, education only.

Where are all my fellow PAs at? 👇 Comment your specialty below. Students - what program are you in?For those of you that...
06/21/2026

Where are all my fellow PAs at? 👇 Comment your specialty below. Students - what program are you in?
For those of you that are less familiar….

PAs: the backbone you don’t always see, but almost always meet.

Physician Associates (PA-Cs) are nationally certified, graduate trained medical providers who diagnose, treat, prescribe, and manage patients across every specialty in medicine. We’re rigorous clinicians and central members of the care team, and nowhere is that more visible than in the ER.

The stats tell the story:

→ Over 12,000 PAs practice emergency medicine, roughly 13% of all certified PAs.

→ More than 75% of U.S. emergency departments have advanced practice clinician representation.

→ PAs and NPs are involved in about 1 in 5 ED visits, and even more in rural departments.

→ Nearly 60% of PA/NP ED visits are co-managed with a physician.

We move the front of house and the back of house: triaging the incoming flow, managing lower acuity patients so physicians can focus on critical cases, and co-managing the complex ones as part of the team.

PAs aren’t a substitute for team based care. We’re the engine that makes it run. We’re not behind the scenes, we’re the reason the doors stay open.


Sources: NCCPA; CDC NHAMCS; Western Journal of Emergency Medicine.

If you could fix ONE symptom by the end of next month, what would it be?Don't be shy. 👇👇👇
05/07/2026

If you could fix ONE symptom by the end of next month, what would it be?

Don't be shy. 👇👇👇

Address

Miami, FL

Website

Alerts

Be the first to know and let us send you an email when Neos Functional Medicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Neos Functional Medicine:

Shortcuts

Share

Category